Goyal L, Zheng H, Abrams T, Miksad R, Bullock A, Allen J
Clin Cancer Res. 2018; 25(1):80-89.
PMID: 30190369
PMC: 6320284.
DOI: 10.1158/1078-0432.CCR-18-0847.
Ikeda M, Mitsunaga S, Ohno I, Hashimoto Y, Takahashi H, Watanabe K
Diseases. 2017; 3(4):360-381.
PMID: 28943630
PMC: 5548259.
DOI: 10.3390/diseases3040360.
Huang T, Su J, Liu C, Shiau C, Chen K
Int J Mol Sci. 2017; 18(6).
PMID: 28594363
PMC: 5486057.
DOI: 10.3390/ijms18061234.
Kim D, Talati C, Kim R
J Gastrointest Oncol. 2017; 8(2):256-265.
PMID: 28480065
PMC: 5401857.
DOI: 10.21037/jgo.2016.09.07.
Wrzesinski S, Taddei T, Strazzabosco M
Clin Liver Dis. 2011; 15(2):423-41, vii-x.
PMID: 21689622
PMC: 3758582.
DOI: 10.1016/j.cld.2011.03.002.
Current management of advanced hepatocellular carcinoma.
Abou-Alfa G, Huitzil-Melendez F, OReilly E, Saltz L
Gastrointest Cancer Res. 2009; 2(2):64-70.
PMID: 19259298
PMC: 2630820.
Chemotherapy with etoposide, doxorubicin, cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma.
Yuan J, Chao Y, Lee W, Li C, Lee R, Chang F
Med Oncol. 2008; 25(2):201-6.
PMID: 18488159
DOI: 10.1007/s12032-007-9013-3.
Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated....
Ishikawa T, Imai M, Kamimura H, Tsuchiya A, Togashi T, Watanabe K
World J Gastroenterol. 2007; 13(41):5465-70.
PMID: 17907289
PMC: 4171280.
DOI: 10.3748/wjg.v13.i41.5465.
Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma.
Jhawer M, Rosen L, Dancey J, Hochster H, Hamburg S, Tempero M
Invest New Drugs. 2006; 25(1):85-94.
PMID: 16957834
DOI: 10.1007/s10637-006-9003-x.
A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma.
Miller K, Loehrer P, GONIN R, Weber G, Ansari R, Pletcher W
Invest New Drugs. 1996; 14(2):207-12.
PMID: 8913842
DOI: 10.1007/BF00210792.
Combination therapy consisting of arterial infusion chemotherapy (EPF, EAP) and transcatheter arterial embolization (TAE).
Yodono H, Takekawa S, Tarusawa K, Ikami I, Kanehira J, Saito Y
Cancer Chemother Pharmacol. 1994; 33 Suppl:S79-83.
PMID: 8137489
DOI: 10.1007/BF00686673.
Randomized controlled study of mitomycin C/carboquone/5-fluorouracil/OK-432 (MQ-F-OK) therapy and mitomycin C/5-fluorouracil/doxorubicin (FAM) therapy against advanced liver cancer.
Sakata Y, Komatsu Y, Takagi S, Saitoh S, Itoh T, Suzuki H
Cancer Chemother Pharmacol. 1989; 23 Suppl:S9-12.
PMID: 2647315
DOI: 10.1007/BF00647230.
Studies on the chemotherapy with 5-fluorouracil in transcatheter arterial chemoembolization (TAE) treated patients with resectable or non-resectable hepatocellular carcinoma. Osaka Study Group on Hepatocellular Carcinoma.
Cancer Chemother Pharmacol. 1989; 23 Suppl:S29-32.
PMID: 2538262
DOI: 10.1007/BF00647235.
Primary liver cancer in Hong Kong.
Shiu W
Cancer Chemother Pharmacol. 1992; 31 Suppl:S143-5.
PMID: 1458565
DOI: 10.1007/BF00687124.
Arterial infusion chemotherapy for advanced hepatocellular carcinoma using EPF and EAP therapies.
Yodono H, Sasaki T, Tarusawa K, Midorikawa H, Saito Y, Takekawa S
Cancer Chemother Pharmacol. 1992; 31 Suppl:S89-92.
PMID: 1333915
DOI: 10.1007/BF00687114.
